OVID Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ovid Therapeutics Inc (OVID) is not a strong buy for a beginner, long-term investor at this moment. The technical indicators show overbought conditions, the financial performance is weak, and there is no recent positive news or significant catalysts. While analysts have given favorable ratings with a higher price target, the lack of strong proprietary trading signals and the negative sentiment from insider and hedge fund trading suggest caution. A 'hold' recommendation is more appropriate until stronger positive catalysts emerge.
The stock is showing bullish momentum with MACD above zero and expanding positively, and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). However, the RSI at 82.178 indicates overbought conditions, suggesting a potential pullback. Key resistance levels are at R1: 1.794 and R2: 1.891, with support at S1: 1.481 and S2: 1.384.
Analyst ratings are favorable, with LifeSci Capital and Roth Capital initiating coverage with 'Outperform' and 'Buy' ratings, and price targets of $4 and $3, respectively. The OV329 drug is viewed as a differentiated therapy in a market needing new medicines.
Hedge funds and insiders are selling significantly, with hedge fund selling increasing by 668.25% and insider selling up by 228.75%. Financial performance in Q3 2025 showed a revenue drop of -23.70% YoY, net income down -13.19% YoY, and EPS down -15.00% YoY. No recent news or congress trading data is available.
In Q3 2025, revenue dropped to $132,000 (-23.70% YoY), net income fell to -$12,158,000 (-13.19% YoY), and EPS declined to -0.17 (-15.00% YoY). Gross margin remained stable at 100%. The financials indicate a struggling company with declining growth metrics.
LifeSci Capital and Roth Capital have initiated coverage with positive ratings ('Outperform' and 'Buy') and price targets of $4 and $3, respectively. Analysts are optimistic about the potential of Ovid's OV329 drug in the epilepsy therapy market.
